Transdiagnostic Effects of Schizophrenia Polygenic Scores on Treatment Outcomes in Major Psychiatric Disorders
Neuropsychiatric Disease and Treatment · 2025-03 · Volume 21 · 547-562
DOI: 10.2147/ndt.s514514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychiatric Disease and Treatment, 2025-03. Verfasst von Alessandro Serretti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Kore University of Enna, Enna, Italy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Schizophrenia polygenic risk scores (SCZ PRS) have emerged as important tools for modulating factors not only in schizophrenia but also in major psychiatric disorders, such as major depression (MDD) and bipolar disorder (BD). Initially developed to capture the common variant risk for SCZ, accumulating evidence highlights the transdiagnostic impact of SCZ PRS on clinical severity, treatment response, and functional outcomes. This review synthesizes recent findings on the relationship between SCZ PRS and treatment outcomes across SCZ, BD, and MDD. A higher SCZ PRS is associated with poorer treatment outcomes, including treatment resistance or non-remission to antidepressants in MDD, reduced antipsychotic response in SCZ, and diminished lithium efficacy in BD. SCZ PRS is also linked to persistent negative symptoms, cognitive impairments, and long-term illness severity in SCZ. While the effect sizes are generally modest, integration of SCZ PRS with environmental factors, multiomics, and neuroimaging may enhance predictive accuracy. Despite variability in reported associations, the overarching evidence supports a transdiagnostic influence of SCZ PRS on disease trajectories and treatment responses. As a promising component of precision psychiatry, SCZ PRS holds potential for guiding more targeted and effective interventions. Future research should focus on combining SCZ PRS with multimodal approaches to fully realize its clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Kore University of Enna, Enna, Italy.
- Oasi Research Institute-IRCCS, Troina, Italy.
- Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.
- Department of Psychiatry, Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia.
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
ORCID-Profile: Alessandro Serretti
Zitieren
APA
Serretti, A., & Baune, B. T. (2025). Transdiagnostic Effects of Schizophrenia Polygenic Scores on Treatment Outcomes in Major Psychiatric Disorders. Neuropsychiatric Disease and Treatment, Volume 21, 547-562. https://doi.org/10.2147/ndt.s514514
Vancouver
Serretti A, Baune BT. Transdiagnostic Effects of Schizophrenia Polygenic Scores on Treatment Outcomes in Major Psychiatric Disorders. Neuropsychiatric Disease and Treatment. 2025;Volume 21:547-562. doi:10.2147/ndt.s514514
BibTeX
@article{Serretti2025,
author = {Serretti, Alessandro and Baune, Bernhard T},
title = {Transdiagnostic Effects of Schizophrenia Polygenic Scores on Treatment Outcomes in Major Psychiatric Disorders},
journal = {Neuropsychiatric Disease and Treatment},
year = {2025},
volume = {Volume 21},
pages = {547--562},
doi = {10.2147/ndt.s514514}
}
EUVIMED